Wednesday, September 23, 2020

Fw: Ref.: (LML) Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy

 

 

Leprosy Mailing List – September 23,  2020

 

Ref.:  (LML) Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy

 

From:  Pieter AM Schreuder, Maastricht, the Netherlands

 

Dear colleagues,

 

Dr. Naafs sent me the following article – of much interest regarding the point Joel Almeida is making in his recent letters.

Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy. By Shannon M. Lenz, Jaymes H. Collins, Nashone A. Ray, Deanna A. Hagge, Ramanuj Lahiri and Linda B. Adams


https://doi.org/10.1371/journal.pntd.0008583

https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008583

 

Conclusions/Significance

The delay in discernible M. leprae growth post-treatment was an excellent indicator of drug efficacy for both early (3–4 months) and late (8–9 months) drug efficacy. Our data indicates that multi-dose PEP may be required to control infection in highly susceptible individuals with subclinical leprosy to prevent disease and decrease transmission.


Regards,


Pieter AM Schreuder


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/310d55e8-4a6a-46d0-82c7-be96be782fb1n%40googlegroups.com.

No comments: